Johnson & Johnson stock (US4781601046): vaccine divestment, Q1 earnings and outlook for US investors

Johnson & Johnson has completed the divestment of its COVID-19 vaccine business to Merck and reported solid Q1 2026 results, while updating investors on its pharma and medtech pipeline. What does this mean for the healthcare giant’s long?term growth story?

Johnson & Johnson has recently advanced its portfolio reshaping by completing the sale of certain remaining COVID?19 vaccine rights to Merck and by presenting first?quarter 2026 results that showed steady growth in its pharmaceutical and medtech businesses, according to company communications and major newswire coverage in May 2026. These steps underline the group’s shift toward higher?margin, innovation?driven segments and away from pandemic?specific products, as reported by multiple financial media outlets in mid?May 2026.

As of: 05/21/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Johnson & Johnson
• Sector/industry: Healthcare; pharmaceuticals and medical technology
• Headquarters/country: New Brunswick, United States
• Core markets: North America, Europe, Asia-Pacific
• Key revenue drivers: Innovative medicines, medical devices, surgical and orthopedic products
• Home exchange/listing venue: New York Stock Exchange (ticker: JNJ)
• Trading currency: US dollar (USD)

Johnson & Johnson: core business model

Johnson & Johnson operates as a diversified healthcare group with two main pillars after the spin?off of its consumer health arm Kenvue in 2023: innovative medicines and medtech devices. The pharmaceutical division focuses on areas such as oncology, immunology and neuroscience, which tend to offer strong pricing power and long product lifecycles when drugs are protected by patents, as reflected in the firm’s recent earnings commentary in April 2026.

The medtech segment supplies surgical instruments, orthopedic implants, vision products and interventional solutions used in hospitals and outpatient centers worldwide. Demand in this business is closely tied to procedure volumes in healthcare systems, which have normalized after the pandemic according to management remarks that accompanied the first?quarter 2026 report in mid?April 2026. For US investors, the combination of recurring device usage and patented drugs creates a mix of cyclical and defensive revenue streams.

Following the separation of Kenvue, Johnson & Johnson has presented itself more clearly as a pure?play research?driven healthcare company, with a sizable share of sales reinvested into R&D each year. In its April 2026 update on Q1 performance, the group emphasized ongoing investments into late?stage drug candidates and next?generation surgical technologies, according to summary figures circulated by major market data providers in late April 2026.

Main revenue and product drivers for Johnson & Johnson

Johnson & Johnson’s pharmaceutical division generates a large portion of group revenue and profit, led by key drugs in oncology and immunology. Among them are treatments for multiple myeloma, prostate cancer and immune?mediated diseases; several products have already reached multibillion?dollar annual sales, according to the company’s 2025 Form 10?K filed with the US Securities and Exchange Commission in February 2026. At the same time, some of these blockbusters are approaching patent expirations over the coming years, which the company has acknowledged as a strategic challenge.

To mitigate future patent cliffs, Johnson & Johnson has built a late?stage pipeline of new medicines targeting areas such as solid tumor oncology, multiple sclerosis and pulmonary arterial hypertension. In its first?quarter 2026 earnings materials released in April 2026, management highlighted progress of several Phase III programs, including candidates in oncology and neuroscience, according to a summary of the call by a leading financial newswire as of 04/16/2026. Successful approvals of these drugs will be crucial for sustaining long?term revenue growth once current blockbusters face generic competition.

The medtech business, meanwhile, is driven by demand for surgical and orthopedic procedures, as well as interventions in cardiology and stroke care. Johnson & Johnson’s April 2026 quarterly presentation pointed to growth in electrophysiology catheters and robotic?assisted surgery solutions compared with the prior year, reflecting hospitals’ efforts to expand minimally invasive procedures, according to coverage by a major business media outlet dated 04/17/2026. For US investors, this exposure to hospital capital spending and procedure volumes provides a lever on the broader US and global healthcare systems.

Geographically, the United States is the largest market for Johnson & Johnson’s medicines and devices, followed by Europe and Asia-Pacific. In its 2025 annual report issued in mid?February 2026, the company noted that US sales accounted for a significant share of group revenue for the year ended December 31, 2025, underscoring its dependence on the US healthcare environment and reimbursement systems. This means that regulatory decisions by agencies such as the US Food and Drug Administration and policy changes affecting Medicare can have a material influence on the company’s prospects.

Industry trends and competitive position

The global healthcare sector is undergoing structural changes driven by aging populations, rising chronic disease burdens and growing payer pressure on drug prices. In this environment, diversified groups like Johnson & Johnson seek to focus on therapies that deliver clear clinical benefits and cost savings. The company’s 2025 annual report, published in February 2026, stressed its commitment to value?based healthcare models and outcome?driven solutions, which can help justify premium pricing in negotiations with insurers and public payers.

Competition remains intense, both from large pharmaceutical peers and from specialty biotech firms developing targeted therapies and cell and gene treatments. Over the past year, Johnson & Johnson has announced several licensing agreements and smaller acquisitions aimed at broadening its presence in oncology and genetic medicine, according to transaction overviews compiled by a major financial data provider in March 2026. These deals highlight the group’s use of partnerships to access external innovation rather than relying solely on internal R&D.

In medical devices, Johnson & Johnson competes with companies such as Medtronic, Stryker and Abbott in fields including orthopedics, cardiovascular devices and surgical instruments. The shift toward minimally invasive and robotic procedures has increased the importance of digital capabilities and data analytics. In a medtech strategy presentation in January 2026, the company underlined its plan to invest further in surgical robotics and connected devices, as summarized by industry trade press in late January 2026. For US investors, Johnson & Johnson’s ability to keep pace with these technology trends will influence its share of procedure volumes in key therapeutic areas.

Why Johnson & Johnson matters for US investors

Johnson & Johnson is one of the largest healthcare companies by market capitalization on the New York Stock Exchange and a longstanding component of major US equity indices. Its stock is widely held by US mutual funds, exchange?traded funds and retirement accounts, making its performance relevant for many diversified portfolios. In mid?April 2026, the company reported that it had delivered modest constant?currency sales growth in the first quarter of 2026 compared with the same period a year earlier, according to a major newswire summary dated 04/16/2026.

The company has historically paid regular dividends and described itself as committed to returning cash to shareholders, although future distributions depend on board decisions and business performance. In its 2025 annual report published in February 2026, Johnson & Johnson pointed out that it had increased its dividend for several consecutive years, while emphasizing that past payments do not guarantee future ones. This track record, combined with exposure to defensive healthcare demand, has made the stock a frequent holding in US income?oriented strategies.

US investors also follow Johnson & Johnson because its results can offer insights into broader healthcare trends, such as procedure volumes in hospitals, utilization rates of new oncology drugs and the impact of policy shifts on drug pricing. When the company discussed its first?quarter 2026 performance in April 2026, management noted that procedure volumes in several surgical categories had remained resilient despite macroeconomic uncertainty, according to a summary of the earnings call by a leading financial news outlet as of 04/17/2026. These comments can serve as indicators for other medtech and hospital?focused companies.

Risks and open questions

Despite its diversified portfolio, Johnson & Johnson faces several risks that US investors monitor closely. One key risk is the potential impact of patent expirations on major drugs over the coming years, which could lead to revenue erosion as generics and biosimilars enter the market. The company outlined these upcoming patent cliffs and associated competitive threats in its 2025 Form 10?K filed with the SEC in February 2026, noting that losses of exclusivity can materially affect sales and margins.

Another area of risk relates to litigation and regulatory scrutiny. Johnson & Johnson has for years dealt with lawsuits concerning certain products, and legal contingencies remain a recurring topic in its filings. In the 2025 annual report, published in mid?February 2026, the company reiterated that it continues to defend itself against various claims while also engaging in settlements in some cases. The ultimate financial impact of these matters can be difficult to quantify in advance and may influence cash flows and reputation.

Policy and pricing pressures in the United States represent a further source of uncertainty. The implementation of drug price negotiation measures under recent US legislation and potential future reforms could affect net prices for some of Johnson & Johnson’s medicines. The company flagged this risk in its February 2026 regulatory filings, pointing out that expanded government bargaining power and reference pricing models could weigh on revenue growth in the medium term. Investors will therefore pay close attention to how the firm positions its pipeline and contracting strategies in response.

Conclusion

Johnson & Johnson is navigating a transition toward a more focused pharmaceutical and medtech profile after exiting its consumer health business and reducing exposure to pandemic?related products. Recent quarterly results and strategic updates in early 2026 show steady demand in key therapeutic areas and ongoing investments in late?stage drug candidates and advanced surgical technologies, according to company filings and financial media coverage in April and May 2026. At the same time, the group faces patent expirations, litigation exposure and increasing pricing pressure in the US market, all of which could influence future growth and profitability. For US investors, the stock represents a large, systemically important healthcare name whose performance is closely tied to innovation execution and the evolving regulatory landscape rather than short?term pandemic dynamics.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.